SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation

Journal of Pharmacological Sciences

Volumn 126, Issue 3, 2014, Pages 198-207

  Wang, Jingjing ^a   Yang, Zhuang ^a,b   Wen, Jiaolin ^a   Ma, Feng ^c   Wang, Fang ^a   Yu, Kun ^a   Tang, Minghai ^a   Wu, Wenshuang ^a   Dong, Yinfeng ^a   Cheng, Xia ^a   Nie, Chunlai ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c INSTITUTE OF BLOOD TRANSFUSION   (China)

Author keywords

AKT; Anti angiogenesis; ERK; Melanoma; P53

Indexed keywords

3 (3 AMINO 4 METHOXYPHENYL) 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL)PROP 2 EN 1 ONE; ALGINIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; CD31 ANTIGEN; CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; 3-(3-AMINO-4-METHOXYPHENYL)-1-(5-METHOXY-2,2-DIMETHYL-2H-CHROMEN- 8-YL)PROP-2-EN-1-ONE; ANGIOGENESIS INHIBITOR; CHALCONE DERIVATIVE; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MIGRATION INHIBITION; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TOXICITY TESTING; TUMOR INVASION; TUMOR VASCULARIZATION; TUMOR VOLUME; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MELANOMA, EXPERIMENTAL; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919761334     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14077FP     Document Type: Article

References (41)

1. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62:357-368.
2. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005;4:206-220.
3. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461-477.
4. Schwarzenberg K, Vollmar AM. Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett. 2013;332:295-303.
5. Rajeev S, Samant RS, Shevde LA. Recent advances in anti- angiogenic therapy of cancer. Oncotarget. 2011;2:122-134.
6. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3-15.
7. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;8:323-331.
8. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815.
9. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. PNAS. 2001;98:10983-10985.
10. Mi C, Ma J, Shi H, Li J, Wang F, Lee JJ, et al. 4′,6-Dihydroxy- 4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation. J Pharmacol Sci. 2014;125:193-201.
11. Wu WS, Ye HY, Wan L, Han XL, Wang GC, Hu J, et al. Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo. Carcinogenesis. 2013;34:1636-1643.
12. Jaffe ER, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745.
13. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, et al. Combination of vascular endothelial growth factor receptor/ platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res. 2008;14:2210-2219.
14. Pang XF, Yi ZF, Zhang XL, Sung B, Qu WJ, Lian XY, et al. Acetyl-11-Keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009;69:5893-5900.
15. Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res. 1997;57:3847-3851.
16. Shrimali RK, Yu ZY, Theoret MR. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171-6180.
17. Gautier J, Minshull J, Lohka M, Glotze M, Hunt T, Maller JL. Cyclin is a component of maturation-promoting factor from Xenopus. Cell. 1990;60:487-494.
18. Utz P, Anderson P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ. 2000;7:589-602.
19. Uchida M, Hanai S, Uematsu N, Sawamoto K, Okano H, Miwa M, et al. Genetic and functional analysis of PARP, a DNA strand break-binding enzyme. Mutat Res. 2001;77:89-96.
20. Cardone MH, Roy H, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
21. Dormond O, Madsen JC, David. The effects of mTOR-Akt Interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem. 2007;282:23679-23686.
22. Bayless KJ, Johnson GA. Role of the cytoskeleton in formation and maintenance of angiogenic sprouts. Journal of vascular research. 2011;48:369-385.
23. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
24. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res. 2011;17:4439-4450.
25. Chen X, Ji P, Yang HW, Yang LL, Zhou S, Zhong L, et al. SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma models. Cell Physiol Biochem. 2013;32:138-153.
26. Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, et al. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS ONE. 2011;6:e22096.
27. Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 2011;11:203.
28. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008;22:1728-1736.
29. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cellular Signalling. 2008;20:21-30.
30. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 2001;20:7779-7786.
31. Arokium H, Ouerfelli H, Velours G, Camougrand N, Vallette FM, Manon S. Substitutions of potentially phosphorylatable serine residues of Bax reveal how they may regulate its interaction with mitochondria. J Biol Chem. 2007;282:35104-35112.
32. Tirado OM, Mateo-Lozano S, Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene. 2005;24:3348-3357.
33. Vega F, Medeiros LJ, Leventaki V. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589-6597.
34. Nakatsu MN, Sainson RCA, Pérez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, et al. VEGF121 and VEGF165 regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest. 2003;83:1873-1885.
35. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516-523.
36. Chou MT, Wang J, Fujita DJ. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochemistry. 2002;3:32.
37. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 2009;28:3412-3422.
38. Elbaum M, Chausovsky A, Levy ET, Shtutman M, Bershadsky AD. Microtubule involvement in regulating cell contractility and adhesion-dependent signalling: a possible mechanism for polarization of cell motility. Biochemical Society symposium. 1999;65:147-172.
39. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 1998;10:123-130.
40. Li Y, Lu X, Qi H, Li X, Xiao X, Gao J. Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and suppression of ERK1/2 MAPK in HeLa cells. J Pharmacol Sci. 2014;125:202-210.
41. Harrison RE, Turley EA. Active Erk regulates microtubule stability in H-ras-transformed cells. Neoplasia. 2001;3:385-394.